GSK Provides an Update on Blenrep (belantamab mafodotin-blmf) US Marketing Authorization

London, UK, 22 November 2022 -- GSK plc (LSE/NYSE: GSK) today announced it has initiated the process for withdrawal of the US marketing authorization for Blenrep following the request of the US Food and Drug Administration (FDA). This request was...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news